MedTrace Logo

Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

NCT04855435 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2026-05-12

No results posted yet for this study

Summary

The Phase I trial is evaluating safety, tolerability, pharmacokinetics and preliminary efficacy of MBS8(1V270) in subjects with advanced solid tumours. The trial is designed to provide data for further clinical development of MBS8(1V270)

Conditions

Interventions

DRUG

MBS8(1V270) and pembrolizumab combination

MBS8(1V270) and pembrolizumab combination

DRUG

MBS8(1V270)

MBS8(1V270) monotherapy

Sponsors & Collaborators

  • MonTa Biosciences ApS

    lead INDUSTRY

Principal Investigators

  • Kristoffer S Rohrberg, MD PhD · University Hospital of Denmark, Department of Oncology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-12
Primary Completion
2027-03-31
Completion
2027-06-30

Countries

  • Denmark
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04855435 on ClinicalTrials.gov